Literature DB >> 11703382

Delayed apoptosis of circulating neutrophils in Kawasaki disease.

H Tsujimoto1, S Takeshita, K Nakatani, Y Kawamura, T Tokutomi, I Sekine.   

Abstract

Circulating polymorphonuclear neutrophils (PMNs) are known to increase in number and are functionally activated in the acute phase of Kawasaki disease (KD). In the present study, we investigated whether the apoptosis of PMNs is deregulated in KD. When the isolated PMNs were cultured in vitro, the proportions of spontaneous apoptotic PMNs (annexin V+ cells and cells with fragmented DNA) were found to be significantly lower (P < 0.01) in the patients with KD (n = 25) than in the patients with a bacterial infection (n = 20) or a viral infection (n = 20), or in healthy children (n = 20). The proportion of circulating Fas-positive PMNs was also significantly lower (P < 0.01) in the acute KD patients than in the other groups. In the acute phase of KD, the proportion of spontaneous apoptotic PMNs showed a significant positive correlation (P < 0.01) with the proportions of circulating Fas-positive PMNs. Furthermore, the agonistic anti-Fas MoAb (CH-11) induced a significant increase in the proportion of apoptotic PMNs in the patients with a viral infection and healthy children, but not in either the patients with KD or the patients with a bacterial infection. In the intracellular expression of anti- and pro-apoptotic proteins, the A1/Bax ratio was significantly higher in acute KD than in the other groups. These findings indicate that PMN apoptosis is inhibited during the acute phase of KD and also suggest that both the resistance against the Fas-mediated death signal and the down-regulation of the mitochondrial apoptotic signalling pathway due to an altered balance of Bcl-2 protein expression are responsible for the delayed PMN apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703382      PMCID: PMC1906184          DOI: 10.1046/j.1365-2249.2001.01675.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia.

Authors:  P A Courtney; A D Crockard; K Williamson; A E Irvine; R J Kennedy; A L Bell
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

Review 2.  Current concepts: immunology. Neutrophils in human diseases.

Authors:  H L Malech; J I Gallin
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

3.  Apoptosis of peripheral blood mononuclear cells in Kawasaki disease.

Authors:  H Y Kim; H G Lee; D S Kim
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

Review 4.  Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins.

Authors:  P M Henson; R B Johnston
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

5.  Bcl-Xl- and Bax-alpha-mediated regulation of apoptosis of human neutrophils via caspase-3.

Authors:  P Weinmann; P Gaehtgens; B Walzog
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

6.  High serum levels of M-CSF and G-CSF in Kawasaki disease.

Authors:  H Igarashi; K Hatake; H Tomizuka; M Yamada; Y Gunji; M Y Momoi
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

7.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

8.  Enhanced neutrophilic functions in mucocutaneous lymph node syndrome, with special reference to the possible role of increased oxygen intermediate generation in the pathogenesis of coronary thromboarteritis.

Authors:  Y Niwa; K Sohmiya
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

9.  Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.

Authors:  L A Smedly; M G Tonnesen; R A Sandhaus; C Haslett; L A Guthrie; R B Johnston; P M Henson; G S Worthen
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

View more
  20 in total

1.  Common variants in CASP3 confer susceptibility to Kawasaki disease.

Authors:  Yoshihiro Onouchi; Kouichi Ozaki; Jane C Buns; Chisato Shimizu; Hiromichi Hamada; Takafumi Honda; Masaru Terai; Akihito Honda; Takashi Takeuchi; Shoichi Shibuta; Tomohiro Suenaga; Hiroyuki Suzuki; Kouji Higashi; Kumi Yasukawa; Yoichi Suzuki; Kumiko Sasago; Yasushi Kemmotsu; Shinichi Takatsuki; Tsutomu Saji; Tetsushi Yoshikawa; Toshiro Nagai; Kunihiro Hamamoto; Fumio Kishi; Kazunobu Ouchi; Yoshitake Sato; Jane W Newburger; Annette L Baker; Stanford T Shulman; Anne H Rowley; Mayumi Yashiro; Yoshikazu Nakamura; Keiko Wakui; Yoshimitsu Fukushima; Akihiro Fujino; Tatsuhiko Tsunoda; Tomisaku Kawasaki; Akira Hata; Yusuke Nakamura; Toshihiro Tanaka
Journal:  Hum Mol Genet       Date:  2010-04-27       Impact factor: 6.150

2.  Neonatal neutrophils with prolonged survival secrete mediators associated with chronic inflammation.

Authors:  Caroline N Nguyen; Patricia M Schnulle; Nasser Chegini; Xiaoping Luo; Joyce M Koenig
Journal:  Neonatology       Date:  2010-06-10       Impact factor: 4.035

3.  Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.

Authors:  Wen Fury; Adriana H Tremoulet; Virginia E Watson; Brookie M Best; Chisato Shimizu; Jennifer Hamilton; John T Kanegaye; Yi Wei; Chiayi Kao; Scott Mellis; Calvin Lin; Jane C Burns
Journal:  Hum Immunol       Date:  2010-06-20       Impact factor: 2.850

4.  Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C.

Authors:  Yanfang P Zhu; Isaac Shamie; Jamie C Lee; Cameron J Nowell; Weiqi Peng; Shiela Angulo; Linh Nn Le; Yushan Liu; Huilai Miao; Hainan Xiong; Cathleen J Pena; Elizabeth Moreno; Eric Griffis; Stephanie G Labou; Alessandra Franco; Lori Broderick; Hal M Hoffman; Chisato Shimizu; Nathan E Lewis; John T Kanegaye; Adriana H Tremoulet; Jane C Burns; Ben A Croker
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

5.  Triptolide as an Alternative to IVIG Therapy for Kawasaki Disease in a Mouse Model.

Authors:  Zong-Ting Yan; Jian-Wen Zou
Journal:  Balkan Med J       Date:  2013-06-01       Impact factor: 2.021

6.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

7.  Bioinformatics identification of hub genes and signaling pathways regulated by intravenous immunoglobulin treatment in acute Kawasaki disease.

Authors:  Hongbiao Huang; Lei Xu; Yueyue Ding; Jie Qin; Chengcheng Huang; Xuan Li; Yunjia Tang; Guanghui Qian; Haitao Lv
Journal:  Exp Ther Med       Date:  2021-05-19       Impact factor: 2.447

8.  In silico Identification of 10 Hub Genes and an miRNA-mRNA Regulatory Network in Acute Kawasaki Disease.

Authors:  Jin Ma; Huan Gui; Yunjia Tang; Yueyue Ding; Guanghui Qian; Mengjie Yang; Mei Wang; Xiudao Song; Haitao Lv
Journal:  Front Genet       Date:  2021-03-25       Impact factor: 4.599

9.  A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease.

Authors:  David Burgner; Sonia Davila; Willemijn B Breunis; Sarah B Ng; Yi Li; Carine Bonnard; Ling Ling; Victoria J Wright; Anbupalam Thalamuthu; Miranda Odam; Chisato Shimizu; Jane C Burns; Michael Levin; Taco W Kuijpers; Martin L Hibberd
Journal:  PLoS Genet       Date:  2009-01-09       Impact factor: 5.917

10.  Neutropenia Is Not Associated With the Outcomes in Patients With Kawasaki Disease.

Authors:  Yunjia Tang; Miao Gang; Weiguo Qian; Jin Ma; Qiuqin Xu; Haitao Lv
Journal:  Front Pediatr       Date:  2021-06-04       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.